看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。) ~1 P5 Y7 B( g
- J: R8 ~4 [7 {! `9 ?, ^. f9 S0 Z/ O. e1 N3 `; j/ B. U, T# E
Currently available feasibility data for possible combination strategies.
/ |; N# f; n5 J7 _————————————————————————————————
3 D0 a8 F, V3 @$ x9 {Combination Feasibility according to preliminary data 8 P* a+ o+ [0 N1 L" f
——————————————————————————————————
7 j Q+ M' p# N" O8 aBevacizumab + sorafenib Yes, reduced dose
% C+ x1 ~) j/ [' s WBevacizumab + sunitinib† No
8 O8 u- f2 M3 {Bevacizumab + temsirolimus Yes
$ ^& I# e( n- y2 y1 v4 [Bevacizumab + everolimus Yes 9 S3 Y' P6 m% n( @# f
Sorafenib + sunitinib ?
2 E9 Z* s( u! L. \% P& e OSorafenib + temsirolimus Yes, reduced dose $ e5 t8 C8 A1 J5 ]( b" _* I: _/ @
Sorafenib + everolimus Yes, reduced dose
+ q4 z1 B% t* p# L* C' NSunitinib + temsirolimus† No ) b! g* N. r' n Q7 Z, \
Sunitinib + everolimus ? 2 i: q/ D- }: M9 d; h
Temsirolimus + everolimus ? ( D. a6 P& H7 E% f$ j$ `+ ?7 ]
————————————————————
' v: ]) T! x1 q0 |) x4 l†Led to US FDA warning.
1 y& q- N6 T) q- {# x?: As yet unattempted combination.
! e- ?9 s! X. F2 x/ W" R( @ |